60 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)
| Therapeutic | Format | Highest Clinical Trial (Jan '20) | Est. Status (Jan '20) | Target | Year Proposed | 100% SI Struc. | 99% SI Struc. | 95-98% SI Struc. |
|---|---|---|---|---|---|---|---|---|
| adintrevimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike | 2021 | no | YES | YES |
| amubarvimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | YES | YES | YES |
| anselamimab | Whole mAb | Phase-III | Active | Light Chain Amyloid Fibrils | 2021 | no | no | no |
| anumigilimab | Whole mAb | Phase-I | Active | CSF3R/CD114 | 2021 | no | no | no |
| bafisontamab | Bispecific Mixed mAb and Fab | Phase-I/II | Active | EGFR/ERBB1/HER1;MET/HGFR | 2021 | YES;no | no;no | no;no |
| barzolvolimab | Whole mAb | Phase-II | Active | KIT/CD117 | 2021 | no | no | no |
| beludavimab | Whole mAb | Phase-II | Active | SARS-CoV-2 Spike RBD | 2021 | no | YES;YES | no |
| dalutrafusp | Whole mAb Fusion | Phase-I | Discontinued | TGFBR2 | 2021 | no | no | no |
| dresbuxelimab | Whole mAb | Phase-I | Active | NT5E/CD73 | 2021 | no | no | no |
| eblasakimab | Whole mAb | Phase-II | Active | IL13RA1/CD213A1 | 2021 | no | no | YES |
| ecleralimab | Whole mAb | Phase-II | Active | TSLP | 2021 | no | no | no |
| elranatamab | Bispecific mAb | Preregistration | Active | TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E | 2021 | no;no | no;no | no;no |
| englumafusp | Fusion Protein | Phase-I | Active | CD19 | 2021 | no | no | no |
| enuzovimab | Whole mAb | Phase-I | Active | SARS-CoV-2 Spike RBD | 2021 | YES | no | no |
| exidavnemab | Whole mAb | Phase-I | Active | SNCA | 2021 | no | no | no |
| fidasimtamab | Bispecific mAb | Phase-I | Discontinued | PDCD1/CD279/PD1;ERBB2/CD340/HER2 | 2021 | no;YES | no;YES | no;YES |
| galegenimab | Whole mAb | Phase-II | Discontinued | HTRA1 | 2021 | YES | no | no |
| ginisortamab | Whole mAb | Phase-I/II | Active | GREM1 | 2021 | no | no | no |
| gresonitamab | Bispecific scFv-scFv-scFc | Phase-I | Active | CLDN18;CD3E | 2021 | no;no | no;no | no;no |
| gumokimab | Whole mAb | Phase-III | Active | IL17A | 2021 | no | no | no |
| iparomlimab | Whole mAb | Phase-I | Active | PDCD1/CD279/PD1 | 2021 | no | no | no |
| ivicentamab | Bispecific mAb | Phase-I/II | Active | CD37;CD37 | 2021 | no;no | no;no | no;no |
| ivonescimab | Bispecific (G1-kappa_scFv) | Preregistration | Active | VEGFA;PDCD1/CD279/PD1 | 2021 | YES;no | no;no | YES;no |
| lepunafusp | Whole mAb Fusion | Phase-I/II | Active | TfR1/CD71 | 2021 | no | no | no |
| ligufalimab | Whole mAb | Phase-II | Active | IAP/CD47 | 2021 | no | no | no |
| livmoniplimab | Whole mAb | Phase-I | Active | LRRC32 | 2021 | no | no | no |
| lomtegovimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | no |
| lorigerlimab | Bispecific Mixed scFv (scFv-CH2-CH3-scFv) | Phase-I/II | Active | PDCD1/CD279/PD1;CTLA4/CD152 | 2021 | no;no | no;no | no;YES |
| manfidokimab | Whole mAb | Phase-II | Active | IL4R/CD124 | 2021 | no | no | no |
| mazorelvimab | Whole mAb | Phase-I/II | Active | Rabies Virus Spike Glycoprotein G | 2021 | no | no | no |
| melredableukin | Whole mAb Fusion | Phase-I | Active | Non-Binding | 2021 | no | YES | YES |
| mupadolimab | Whole mAb | Phase-III | Active | NT5E/CD73 | 2021 | no | no | no |
| nofazinlimab | Whole mAb | Phase-III | Active | PDCD1/CD279/PD1 | 2021 | no | no | no |
| ormutivimab | Whole mAb | Approved | NFD | Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1 | 2021 | no | no | no |
| pivekimab | Whole mAb | Phase-I/II | Active | IL3RA/CD123 | 2021 | no | no | no |
| pulocimab | Whole mAb | Phase-II | Active | KDR/CD309/VEGFR2 | 2021 | no | YES | no |
| quisovalimab | Whole mAb | Phase-II | Active | TNFSF14/CD258 | 2021 | no | no | no |
| rimteravimab | Mixed Nanobody (VHH-CH2-CH3 dimer) | Phase-I/II | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | no |
| rocatinlimab | Whole mAb | Phase-III | Active | TNFRSF4/CD134/OX40 | 2021 | no | no | no |
| romlusevimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | no | YES | no |
| rulonilimab | Whole mAb | Phase-II/III | Discontinued | PDCD1/CD279/PD1 | 2021 | no | no | no |
| simridarlimab | Bispecific Mixed mAb/VH-VH-CH2-CH3 | Phase-I | Active | IAP/CD47;PDL1/CD274 | 2021 | no;no | no;no | no;no |
| sirexatamab | Whole mAb | Phase-II | Active | DKK1 | 2021 | no | no | no |
| socazolimab | Whole mAb | Preregistration | Active | PDL1/CD274 | 2021 | no | no | no |
| sotevtamab | Whole mAb | Phase-II | Active | CLU | 2021 | no | no | no |
| suciraslimab | Whole mAb | Phase-III | Active | SIGLEC2/CD22 | 2021 | no | no | no |
| tagitanlimab | Whole mAb | Preregistration | Active | PDL1/CD274 | 2021 | no | no | no |
| tamgiblimab | Whole mAb | Phase-II | Active | TIGIT/WUCAM/VSTM3 | 2021 | no | no | no |
| tarcocimab | Whole mAb | Phase-III | Active | VEGFA | 2021 | YES | no | YES |
| tecaginlimab | Bispecific mAb | Phase-I/II | Active | CD40;TNFRSF9/CD137/4-1BB | 2021 | no;no | no;no | no;no |
| teropavimab | Whole mAb | Phase-II | Active | HIV-1 gp120 CD4bs | 2021 | no | YES | no |
| trinbelimab | Whole mAb | TBC | Active | RhD/CD240D/RhPI | 2021 | no | no | no |
| tuvonralimab | Whole mAb | Phase-III | Active | CTLA4/CD152 | 2021 | no | no | no |
| ubamatamab | Bispecific mAb | Phase-II | Active | MUC16/CA125;CD3E | 2021 | no;no | no;no | no;no |
| ulenistamab | Whole mAb | Phase-II | Active | PAUF | 2021 | no | no | no |
| upanovimab | Whole mAb | Phase-II/III | Active | SARS-CoV-2 Spike RBD | 2021 | no | no | YES |
| vepsitamab | Bispecific (scFv-scFv-scFc) | Phase-I | Active | MUC17;CD3E | 2021 | no;no | no;no | no;no |
| voxalatamab | Bispecific mAb | Phase-I | Active | FOLH1/GCPII/PSMA;CD3E | 2021 | no;no | no;no | no;no |
| xeligekimab | Whole mAb | Phase-III | Active | IL17A | 2021 | no | no | no |
| zamerovimab | Whole mAb | Phase-I/II | Active | Rabies Virus Spike Glycoprotein G | 2021 | no | no | no |
Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.
Download a spreadsheet of all therapeutic sequences/structures (last list - PL128): xlsx / csv
If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
